-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ka26ScdBDfKTn61936K+i6s8lD3dy7jt6lBVCufcHH4E6Gt6R4lLDrlyBExGDPDl
 f51shznl8E8D4YOJ0pTBUQ==

<SEC-DOCUMENT>0000927946-03-000141.txt : 20030701
<SEC-HEADER>0000927946-03-000141.hdr.sgml : 20030701
<ACCEPTANCE-DATETIME>20030701171613
ACCESSION NUMBER:		0000927946-03-000141
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20030630
ITEM INFORMATION:		Other events
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20030701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		03768816

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>basform8k.htm
<DESCRIPTION>BIOANALYTICAL SYSTEMS, INC.
<TEXT>
<HTML>
<HEAD>
<Title>Bioanalytical Systems, Inc. - Form 8K</title></head>
<BODY>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></FONT><br>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<b>Washington, D.C. 20549</b></font></P>
<br>

<hr width=30% noshade>

<p align=center><FONT FACE="Times New Roman, Times, Serif" size=4>
<b>FORM 8-K</b><BR><br>
<B>CURRENT REPORT</B><BR><br>
<b><small>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</small></b>
</font></p>
<hr width=30% noshade>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Date of Report (Date of earliest event reported):&nbsp;&nbsp;<b>June 30, 2003</b>
</font></p>
<br>
<br>
<br>
<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=4>
<b><u>BIOANALYTICAL SYSTEMS, INC.</u></b><br>
<small><small><small>(Exact name of registrant as specified in its charter)</small></small></small>
</font></P>

<table width=95% border=0>
<tr valign=bottom><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u><B>Indiana</B></u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
<B>0-23357</B></u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
<B>35-1345024</B></u></font></td></TR>

<TR VALIGN=TOP>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(State or other jurisdiction of<br>incorporation or organization)</font></TD>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Commission File Number)</font></td>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(IRS Employer Identification No.)</font></td></TR>
<tr><TD><br></TD></tr>

<TR VALIGN=bottom><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<B>2701 Kent Avenue</B><br>
<u><B>West Lafayette, IN</B></u></font></TD>
<TD></TD> <td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><br>
<u><B>47906-1382</B></u></font></td></TR>
<TR VALIGN=top><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Address of principal executive offices)</font></TD><TD>
</TD><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Zip Code)</font></td></TR>
<tr><TD></TD></tr>
<TR VALIGN=top><TD> </TD><TD align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u><B>(765) 463-4527</B></u></font></TD></TR>
<TR VALIGN=top><TD> </TD><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Registrant's telephone number, including area code)</font></TD></TR>
</TABLE>


<PAGE>


<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Item 5.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On July 1, 2003, Bioanalytical Systems, Inc. (the "Company")
issued the press release filed herewith as Exhibit 99.1, and incorporated
herein by reference, announcing the completion of its acquisition of
PharmaKinetics Laboratories, Inc.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Item 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following exhibits are
filed as a part of this report:</font></P>

         <P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Exhibits</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press release, dated July 1,
2003, announcing the completion its acquisition of PharmaKinetics Laboratories,
Inc.

</font></P>


<PAGE>


<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
<B>SIGNATURES</B></font></P>
<BR>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></P>


<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE width=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
Date:&nbsp;&nbsp;&nbsp;&nbsp;July 1, 2003</font></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>BIOANALYTICAL SYSTEMS, INC.</U><BR>
(Registrant)<BR>
<BR>
<BR>
<BR>
By:&nbsp;&nbsp;/s/&nbsp;&nbsp;Douglas P. Wieten<hr>
Douglas P. Wieten<BR>
Vice President - Finance,<BR>
Chief Financial Officer and Treasurer<BR>
</FONT></TD>
</TR>
</TABLE>
<BR>

<PAGE>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
<B><u>Exhibit Index</u></B></font></P>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Header" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=BOTTOM>
<TH WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item Number<BR>
assigned in<BR>
<U>Regulation S-K</U>
</FONT></TH>
<TH WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit</U></FONT></TH>
<TH WIDTH=65%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Description of Exhibits</U>
</FONT></TH>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
99</FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
(99.1)</FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Press release dated July 1, 2003.</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit991.htm
<DESCRIPTION>PRESS RELEASED DATED JULY 1, 2003
<TEXT>
<HTML>
<HEAD>
<TITLE>BASi Exhibit 99.1</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Head Right" FSL="Default" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<B><U>Exhibit 99.1</U></B> </FONT></P>
<BR>

<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<B>BASi PharmaKinetics Acquisition Completed </B></FONT></P>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
WEST LAFAYETTE, Ind. &#151; (BUSINESS WIRE) &#151; July 1, 2003 &#151;
Bioanalytical Systems, Inc. (Nasdaq:BASI &#151; News) is pleased to announce
completion of its acquisition of PharmaKinetics Laboratories, Inc. (OTCBB:PKLB
&#151; News) located in Baltimore, Maryland. A favorable vote on the merger was
obtained from PKLB shareholders at the Special Meeting of Shareholders on June
30, 2003, and consummation of the merger was completed immediately
following.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&#147;The acquisition of PKLB will add to BASi&#146;s strong management team and
allow BASi to expand its Product and Contract Services business units, also
adding new capabilities to the latter,&#148; said Dr. Peter T. Kissinger, BASi
Chairman and CEO. &#147;BASi and PKLB are highly complementary. The BASi growth
plan called for a location on the East Coast, which we found in PKLB. BASi now
has offices on the East and West Coasts, as well as in the Midwest, providing
much better access to valued clients.&#148;</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
According to Dr. James Wilkinson, President and CEO of PKLB, &#147;We are
excited to be a part of BASi and to move forward from here. BASi&#146;s market
position as a respected provider of products and laboratory services will add
significant value for both our employees and clients.&#148;</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Headquartered in West Lafayette, Indiana BASi provides contract development
services and research equipment to pharmaceutical, medical device and
biotechnology companies. These companies use BASi&#146;s services and equipment
to improve the speed and efficiency of preclinical, clinical and analytical
development of their products. Scientists engaged in drug metabolism studies,
pharmacokinetics and basic neuroscience research at pharmaceutical research
organizations are BASi&#146;s principal clients. BASi&#146;s services group
provides screening and pharmacological testing, preclinical/safety testing,
formulation development, regulatory compliance and quality control
testing.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
PharmaKinetics Laboratories, Inc. is a contract research organization providing
a range of clinical research and development services to the worldwide
pharmaceutical and biotechnology industries in the development of prescription
and non-prescription drug products.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
This release contains forward-looking statements that are subject to risks and
uncertainties including, but not limited to, risks and uncertainties related to
the development of products and services, changes in technology, industry
standards and regulatory standards, and various market and operating risks
detailed in the company&#146;s filings with the Securities and Exchange
Commission.</FONT></P>
<BR>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 1-TNR" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<I>Contact:</I></FONT></TD></tr>
</TABLE>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;</FONT></TD>
<TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc.<BR>
Michael P. Silvon, 765/497-5831<BR>
silvon@bioanalytical.com<BR>
OR<BR>
KCSA Worldwide<BR>
Evan Smith, 212/896-1251<BR>
Erica Pettit, 212/896-1248</FONT></TD>
</TR>
</TABLE>
<BR>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
